Frankfurt
26.05.25 | 08:10
0,007 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.06. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.06.2025 | 602 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 02.06.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.06.2025ISIN NameCA19243C1005 COGNETIVITY... ► Artikel lesen | |
| 26.05. | Delisting of Lipidor AB from Nasdaq First North Growth Market | 246 | GlobeNewswire | On May 26, 2025, Lipidor AB was declared bankrupt by the Stockholm District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist... ► Artikel lesen | |
| 26.05. | XFRA L7R: AUSSETZUNG/SUSPENSION | 121 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLIPIDOR AB L7R SE0012558617... ► Artikel lesen | |
| 26.05. | Suspension of Trading in Lipidor AB at FNSE | 182 | GlobeNewswire | 2025-05-26T06:33:44Z
Suspension
At Trading Venue FNSE
Due to Non Disclosure Of
Inside Information About The Issuer Or Financial Instrument
Ongoing:
True
Comments: Nasdaq Stockholm has, to the extent... ► Artikel lesen | |
| 25.05. | Lipidor AB: Lipidor applies for bankruptcy | 233 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 25th May 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the Company's board has resolved to file for bankruptcy on behalf of the Company. The... ► Artikel lesen | |
| 24.05. | Lipidor AB: Lipidor announces today negative results from the company's Phase III clinical study of AKP02G2 for psoriasis | 124 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 24th May 2025 - (Nasdaq First North: LIPI) reports negative results from a Phase III clinical study of the AKP02G2 cutaneous spray for mild to moderate plaque psoriasis. The study... ► Artikel lesen | |
| LIPIDOR Aktie jetzt für 0€ handeln | |||||
| 19.05. | Lipidor AB: Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2 | 142 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 19th May 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study of AKP02G2 for the treatment of psoriasis has reached... ► Artikel lesen | |
| 17.03. | Lipidor AB: Lipidor announces all patients enrolled in ongoing Phase III study | 160 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 17th March 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that all patients in the ongoing Phase III study for the drug candidate AKP02G2 have been... ► Artikel lesen | |
| 28.02. | Lipidor AB: Lipidor AB (publ) publishes year-end report for 2024 | 233 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 28th February 2025 - Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January - December 2024. The report is available... ► Artikel lesen | |
| 21.01. | Lipidor AB: Lipidor announces half of patients enrolled in ongoing Phase III study | 544 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 21st January 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that half of the patients in the ongoing Phase III study for the drug candidate AKP02G2... ► Artikel lesen | |
| 20.11.24 | Lipidor AB: Lipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025" | 167 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 20 November 2024 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today provides an update on the business from CEO Ola Holmlund, also announcing a company presentation... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORAMED PHARMACEUTICALS | 1,894 | +2,46 % | Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical | Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology
Accelerating multiple late-stage cancer therapies... ► Artikel lesen | |
| OPUS GENETICS | 1,096 | +2,43 % | Opus Genetics, Inc. - 8-K, Current Report | ||
| VERTICAL AEROSPACE | 4,100 | -1,44 % | Patrick Ky, Former EASA Executive Director, Joins Vertical Aerospace's Board | Former Executive Director of the European Union Aviation Safety Agency (EASA) brings unrivalled global regulatory experience
Appointment reinforces Vertical's pathway to certify its VX4... ► Artikel lesen | |
| BOIRON | 20,950 | -3,01 % | Boiron USA: Boiron's Camilia Tummy Receives Top Honors from Baby Innovation Awards | Newtown Square, Pennsylvania--(Newsfile Corp. - June 26, 2025) - Camilia Tummy® has received the "Baby Accessory Product of the Year" in the 2025 Baby Innovation Awards. Now in its fifth year, this... ► Artikel lesen | |
| PACIRA BIOSCIENCES | 23,200 | +1,75 % | Johnson & Johnson MedTech, Pacira BioSciences Partner To Promote ZILRETTA For Knee OA Pain | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson MedTech - the medical technology business segment of Johnson & Johnson (JNJ) has entered a strategic co-promotion agreement with Pacira BioSciences... ► Artikel lesen | |
| RED LIGHT HOLLAND | 0,020 | 0,00 % | Red Light Holland Corp.: Red Light Holland Reports First Quarter 2026 Results | Toronto, Ontario--(Newsfile Corp. - August 28, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in... ► Artikel lesen | |
| INNOCARE PHARMA | 2,060 | +7,85 % | DMS Group: An International Alliance For European Technological Sovereignty In Medical Imaging - Capital Increase Of A Total Amount Of Eur 6.9 Million Reserved For Innolux, Innocare, Bpifrance And NextStage AM | A major international industrial alliance, supported by major institutional investors.
DMS Group, a fast-growing European industrial player, is joining forces with two listed Asian technology... ► Artikel lesen | |
| PHIBRO ANIMAL HEALTH | 31,000 | -1,90 % | Dividendenbekanntmachungen (03.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AEGON LTD BMG0112X1056 - 0,19 EUR AIR LEASE CORPORATION US00912X3026 0,22 USD 0,1889 EUR AMKOR TECHNOLOGY INC US0316521006 0,0826... ► Artikel lesen | |
| BAYER | 28,035 | +2,19 % | DAX und Bitcoin höher: Nvidia mit Zahlen, Commerzbank, Deutsche Bank, Siemens Energy, Bayer ... | Der DAX hat am Dienstag erneut leichte Verluste verbucht. Er ging mit einem Minus von 0,5 Prozent bei 24.152,87 Zählern aus dem Handel. Zum Start in den heutigen Mittwoch sieht es wieder etwas freundlicher... ► Artikel lesen | |
| MERCK KGAA | 109,60 | +1,48 % | Milliardenmarkt Multiple Sklerose - BioNxt Solutions, Biogen, Merck KGaA, Novartis | Multiple Sklerose (MS) ist eine entzündliche und chronische Erkrankung des zentralen Nervensystems im Gehirn und Rückenmark des Menschen. Dabei greift das Immunsystem durch eine Fehlregulation die eigenen... ► Artikel lesen | |
| NOVO NORDISK | 48,630 | +0,62 % | Schnelle 30 % Rendite möglich? Novo Nordisk, D-Wave, NetraMark Aktie! | Drei völlig unterschiedliche Unternehmen, doch alle mit Renditechancen: Der KI-Spezialist NetraMark steht vor einem charttechnischen Ausbruch. NetraAI hat ChatGPT und DeepSeek geschlagen und gewinnt... ► Artikel lesen | |
| GSK | 16,955 | +1,71 % | DEUTSCHE BANK RESEARCH stuft GSK auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für GSK mit einem Kursziel von 1450 Pence auf "Hold" belassen. Dies schrieb Analyst Emmanuel Papadakis in seiner am Mittwoch... ► Artikel lesen | |
| METSERA | 35,660 | 0,00 % | Metsera, Inc.: Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress | MET-097i (fully biased once-monthly GLP-1 RA) VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog)... ► Artikel lesen | |
| HARROW | 37,340 | -1,03 % | Harrow, Inc.: Harrow Health, Inc. Announces Second-Quarter 2025 Financial Results | Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA... ► Artikel lesen | |
| ROCKET LAB | 37,400 | -11,79 % | Rocket Lab Stock Settles Back To Earth After Hitting Stratosphere |
LIPIDOR AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,007 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIPIDOR AB finden Sie auf Wallstreet Online.